Every Form 4 that Edgewise Therapeutics, Inc. (EWTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow EWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EWTX filings page.
Edgewise Therapeutics, Inc. reported that Chief Financial Officer Michael Nofi received a grant of 48,750 stock options on August 12, 2026. These options have an exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expire on August 12, 2036. The amendment clarifies that an earlier filing incorrectly showed a $0.00 exercise price due to a clerical error. According to the vesting terms, 1/48 of the options vest each month beginning on September 12, 2026, contingent on his continued service.
Edgewise Therapeutics, Inc. reported an amended insider transaction for its CMO, Joanne M. Donovan. She received a grant of 65,000 stock options to purchase common stock at an exercise price of $43.56 per share, expiring on August 12, 2036. The company states this amendment corrects a clerical error in the originally reported exercise price. The options vest in equal monthly installments over four years starting on September 12, 2026, contingent on her continued service.
Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell received a grant of stock options for 65,000 shares of common stock on August 12, 2026. An amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date.
The options have an expiration date of August 12, 2036. According to the vesting terms, 1/48 of the shares vest each month beginning September 12, 2026, contingent on Russell continuing as a service provider through each vesting date.
Edgewise Therapeutics, Inc. reported that its General Counsel, John R. Moore, received a grant of a stock option covering 65,000 shares of common stock. The option has a corrected exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expires on August 12, 2036. According to the vesting terms, 1/48th of the shares vest each month beginning on September 12, 2026, contingent on his continued service.
Edgewise Therapeutics, Inc. reported that Chief Business Officer Behrad Derakhshan received a grant of 100,000 stock options to purchase common stock. This amendment corrects the option’s exercise price to $43.56 per share, reflecting the fair market value on the grant date. The options vest in 1/48 monthly installments beginning September 12, 2026, contingent on continued service, and expire on August 12, 2036. Following this grant, Derakhshan holds 100,000 derivative securities directly.
Edgewise Therapeutics, Inc. granted its Chief Financial Officer, Michael Nofi, new equity awards. 24,375 Restricted Stock Units were awarded for no additional cash consideration, each RSU representing one share of common stock, vesting in four equal annual installments starting August 12, 2027. In addition, a stock option for 48,750 shares of common stock with a stated exercise price of $0.0000 per share was granted, expiring August 12, 2036 and vesting as to 1/48 of the shares each month beginning September 12, 2026, subject to continued service.
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported multiple equity transactions. On August 12, 2026, she exercised 12,812 Restricted Stock Units into common stock at $0.00 per share and received new awards of 32,500 RSUs and 65,000 stock options, each for no additional cash consideration. The options cover 65,000 shares of common stock and vest in 48 equal monthly installments beginning September 12, 2026. On August 12–13, 2026, she sold a total of 9,441 shares of common stock at average prices between $43.12 and $44.57 per share. Footnotes state that 2026-08-12 sales were executed as "sell-to-cover" transactions to satisfy statutory tax withholding on RSU vesting, and the August 13 sale of 2,919 shares was made under a pre-arranged Rule 10b5-1 Plan adopted on December 26, 2025.
Edgewise Therapeutics, Inc. Chief Scientific Officer Alan J. Russell reported multiple equity transactions on August 12, 2026. He exercised previously granted Restricted Stock Units into 5,781 and 7,031 shares of common stock, then sold a total of 5,901 shares in market transactions solely to cover statutory tax-withholding obligations under a "sell-to-cover" arrangement, which the company describes as not a discretionary sale. He also received new equity awards: 32,500 RSUs that vest in four equal annual installments beginning August 12, 2027, and a stock option for 65,000 shares, vesting 1/48th monthly starting September 12, 2026.
Edgewise Therapeutics, Inc. General Counsel John R. Moore reported a mix of equity transactions on August 12, 2026. He exercised Restricted Stock Units into 12,499 shares of common stock and sold 5,016 shares in a sell‑to‑cover transaction to satisfy statutory tax withholding obligations. He also received new awards of 32,500 Restricted Stock Units vesting annually beginning August 12, 2027, and a stock option covering 65,000 shares, vesting monthly beginning September 12, 2026.
Edgewise Therapeutics, Inc. reported that Chief Business Officer Derakhshan Behrad had RSUs for 5,781 and 7,500 shares convert into common stock on August 12, 2026. A total of 5,100 shares were sold in multiple trades to cover statutory tax withholding obligations under a sell-to-cover arrangement, which the company states was not a discretionary sale. Behrad also received equity awards of 50,000 RSUs, vesting in four annual installments beginning August 12, 2027, and a stock option for 100,000 shares vesting monthly over 48 months beginning September 12, 2026.
Edgewise Therapeutics, Inc. President and CEO Kevin Koch reported multiple equity transactions on August 12, 2026. Previously granted RSUs converted into 17,969 and 21,875 shares of common stock, with a total of 17,971 shares sold in “sell-to-cover” trades solely to satisfy statutory tax withholding obligations, not as discretionary sales. Koch also received new awards of 100,000 RSUs, vesting in four annual installments beginning August 12, 2027, and 200,000 stock options with a $43.56 exercise price, vesting monthly over four years starting September 12, 2026.
Edgewise Therapeutics director Jonathan D. Root received a grant of stock options to acquire 16,377 shares of common stock on June 5, 2026. The options have an exercise price of $35.5900 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of shareholders, and Root now directly holds options for 16,377 shares from this grant.
Edgewise Therapeutics, Inc. reported that Chief Scientific Officer Alan J. Russell executed an exercise-and-sell transaction involving company stock. He exercised stock options to acquire a total of 200,000 shares of common stock, including 69,648 shares at an exercise price of $0.18 per share and 130,352 shares at an exercise price of $0.45 per share. On the same date, he sold 69,648 shares at an average price of $39.4089 per share and 130,352 shares at an average price of $39.4060 per share in open-market transactions, for total sales of 200,000 shares. Following these transactions, he directly holds 94,203 shares of common stock and retains 1,077,717 stock options with a $0.18 exercise price expiring on June 27, 2032.
Fox Jonathan C reported acquisition or exercise transactions in this Form 4 filing.
Edgewise Therapeutics director Jonathan C. Fox received a grant of 319 shares of Common Stock. The shares were awarded at a price of $0.00 per share as a compensation-related grant, not an open-market purchase. Following this award, Fox directly holds 24,833 shares of Edgewise Therapeutics common stock.
Edgewise Therapeutics director Laura Brege received a new stock option grant covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day before the 2027 annual meeting of stockholders.
After this grant, Brege holds 16,377 stock options directly, all tied to this award.
Edgewise Therapeutics director and 10% owner Peter A. Thompson received a grant of stock options for 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036.
According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Thompson holds 16,377 stock options directly.
Edgewise Therapeutics director Arlene Morris received a grant of stock options covering 16,377 shares of common stock. The options have an exercise price of $35.59 per share and expire on June 5, 2036. According to the terms, 100% of these options will vest on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. Following this grant, Morris holds stock options for 16,377 underlying shares directly.
Edgewise Therapeutics, Inc. director Edris Badreddin received new equity-based compensation. On June 5, 2026, he was granted stock options for 8,188 shares of common stock at an exercise price of $35.59 per share, expiring on June 5, 2036. He also received 5,619 Restricted Stock Units (RSUs). According to the terms, 100% of both the options and RSUs will vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of stockholders. These are compensation grants, not open‑market purchases or sales.
Edgewise Therapeutics, Inc. director Martin Christopher Nathan reported receiving a grant of stock options on Common Stock. The award covers 16,377 stock options with an exercise price of $35.59 per share, giving him the right to buy the same number of common shares in the future.
According to the grant terms, all of these options vest 100% on the earlier of June 5, 2027 or the business day before the company’s 2027 annual meeting of stockholders. The options expire on June 5, 2036, and he held 16,377 derivative securities from this grant following the transaction.
Edgewise Therapeutics director Jonathan C. Fox received a grant of stock options, giving him rights to acquire 16,377 shares of common stock. The options have an exercise price of $35.59 per share and fully vest on the earlier of June 5, 2027 or the business day before the 2027 annual stockholder meeting. Following this grant, he holds 16,377 stock options directly as reported in this filing. This is a compensation-related award rather than an open-market purchase or sale.
Edgewise Therapeutics, Inc. CMO Joanne M. Donovan reported an option exercise and related stock sales. On May 5, 2026, she exercised stock options to acquire 50,000 shares of common stock at $7.08 per share, then sold 50,000 shares at an average price of $38.568.
On May 4, 2026, she also sold 5,230 shares at an average price of $31.2931. The filing notes both sales were made in multiple transactions within disclosed price ranges and were effected under a Rule 10b5-1 Plan adopted on December 26, 2025. Following these transactions, she directly holds 4,367 shares of Edgewise Therapeutics common stock.
Edgewise Therapeutics, Inc. director Jonathan C. Fox received a grant of 339 shares of Common Stock as a stock award. The shares were acquired at no cash cost to him and increase his direct ownership to 24,514 shares following the transaction on April 1, 2026.
Edgewise Therapeutics, Inc. Chief Medical Officer Joanne M. Donovan reported an option exercise and related share sale. On April 1, 2026, she exercised stock options to acquire 28,662 shares of common stock at $7.08 per share, then sold 28,662 shares of common stock at an average price of $32.3109 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. After these transactions, she directly holds 9,597 shares of Edgewise Therapeutics common stock.
Edgewise Therapeutics CMO Joanne M. Donovan exercised stock options to acquire 21,338 shares of common stock at an exercise price of $7.08 per share, then sold 21,338 shares in an open-market transaction at an average price of $32.1168 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025, meaning the trades were scheduled in advance. After these transactions, she directly holds 9,597 shares of common stock and 153,662 stock options that vest in equal monthly installments over 48 months beginning on September 17, 2023, and expire on August 17, 2033.
Edgewise Therapeutics CMO Joanne M. Donovan reported selling common stock in open-market transactions. On March 27, 2026, she sold a total of 16,358 shares of Edgewise Therapeutics, Inc. common stock in two sales at an average price of about $30.98 per share.
After these transactions, she directly holds 9,597 shares of common stock. Footnotes explain the shares sold were accumulated through multiple purchases under the company’s 2021 Employee Stock Purchase Plan between May 2022 and November 2024, including 594 shares purchased on November 17, 2025. The sales occurred across individual trades priced between $30.49 and $31.68.
Edgewise Therapeutics, Inc. director Edris Badreddin reported option exercises and related share sales. On January 21, 2026, he exercised multiple stock options for Edgewise common stock at exercise prices ranging from $0.39 to $1.93 per share, converting them into common shares held directly.
The same day, he sold shares of Edgewise common stock in several transactions marked with code "S". These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 24, 2025, at an average sale price of $29.44 per share, with individual trades occurring between $29.00 and $29.77. Following the reported transactions, Badreddin directly owned 19,820 shares of Edgewise common stock.
Edgewise Therapeutics, Inc. (EWTX) reported a routine equity compensation grant to a director on a Form 4. On November 19, 2025, the reporting person received stock options to purchase 45,150 shares of common stock at an exercise price of $22.34 per share. These options begin vesting on December 19, 2025, with 1/36th of the shares vesting each month, so full vesting occurs over three years as long as the director continues as a service provider through each vesting date. The options have an expiration date of November 19, 2035, meaning they can be exercised anytime after vesting and before that date, subject to the applicable plan and agreement terms.
Edgewise Therapeutics (EWTX) filed a Form 4 showing insider activity. On 11/12/2025, a Director and Chief Scientific Officer exercised stock options and sold shares the same day. The insider exercised 100,000 options at an exercise price of $0.18 (code M) and sold 100,000 shares of common stock at an average price of $21.1245 (code S), with trades executed between $21.00 and $21.35.
Following these transactions, the insider directly beneficially owned 23,400 common shares. In addition, 1,147,365 derivative securities (stock options) remained beneficially owned. The exercised option referenced had become exercisable on 06/27/2021 and carries an expiration date of 06/27/2032.
Edgewise Therapeutics, Inc. director reports open-market share purchase. A reporting person who serves as a director of Edgewise Therapeutics, Inc. (EWTX) bought 10,700 shares of common stock on 11/11/2025 in an open-market transaction coded as a purchase. The shares were acquired at an average price of $18.6358 per share, with multiple trades executed in a price range from $18.55 to $18.65. Following this transaction, the director beneficially owns 23,702 shares of Edgewise Therapeutics common stock, held directly. The reporting person has indicated a willingness to provide detailed trade-by-trade pricing information upon request.
Edgewise Therapeutics, Inc. (EWTX) reported new equity awards to its Chief Financial Officer, Michael Nofi. On 11/10/2025, he received 43,750 restricted stock units (RSUs) that convert into the same number of common shares, vesting in four equal annual installments beginning on November 10, 2026. He was also granted stock options to purchase 262,500 shares of common stock at an exercise price of $18.28 per share. One quarter of these options vest on November 10, 2026, and the remaining options vest in equal monthly installments over the following three years, contingent on his continued service.